AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)
Description: Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
Study NCT04446091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
Description: Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
Study NCT00504777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study NCT00504777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week po or parenteral
Study NCT02627118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRESENIUS 160NR
Description: 2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
Study NCT02627118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPRO ELISIO-15H
Description: 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
Study NCT03274973 — intervention group
Intervention type: DRUG
Intervention: Zomacton
Description: Injection
Study NCT03327272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
Study NCT03327272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline at surgical site prior to incision closure
Study NCT02224547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (Fractionated stereotactic body radiation)
Description: Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
Study NCT05146089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: 30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
Study NCT02494856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with Naproxen
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
Study NCT02494856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with Naproxen and Esomeprazole
Description: After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
Study NCT00190164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular hole surgery with alleviated positioning
Description: Macular hole surgery with alleviated positioning
Study NCT00190164 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Macular hole surgery with no alleviated positioning
Description: Macular hole surgery with no alleviated positioning
Study NCT00428428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isoproterenol
Description: ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
Study NCT05146089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified Oxford test
Description: An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
Study NCT05146089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Bosentan 62.5 mg
Description: Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
Study NCT05146089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response test
Description: Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
Study NCT00555243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Simulation training
Description: five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
Study NCT00555243 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Surgical Education
Description: Traditional surgical teaching (no simulator)
Study NCT04510181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acid-based blend
Description: blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
Study NCT02597322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXITINIB
Description: Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
Study NCT00911651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: 400 µg inhalation once
Study NCT00911651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: 80 µg inhalation once
Study NCT00639522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel and capecitabine
Description: Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
Study NCT05719753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camstent Coated Catheter
Description: The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
Study NCT05719753 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Bard Catheter
Study NCT02223104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexima Active
Study NCT02223104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensura
Study NCT04674189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Intramuscular injection
Study NCT00428428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoproterenol
Description: ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
Study NCT04674189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT02126852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG, one-dimensionally)
Description: Neuromuscular monitoring
Study NCT02126852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG, three-dimensionally)
Description: Neuromuscular monitoring
Study NCT02126852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Neuromuscular monitoring
Study NCT00689182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monthly phlebotomy x 12 months
Description: All patients will receive monthly phlebotomies.
Study NCT01637077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Given PO
Study NCT01637077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01637077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01637077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT04212351 — intervention group
Intervention type: GENETIC
Intervention: Frameshift Array blood sample test
Description: Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
Study NCT03879174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Tamoxifen
Description: The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage.
Study NCT04198389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PARTIAL KNEE REPLACEMENT
Description: PARTIAL KNEE REPLACEMENT
Study NCT01224834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual tablet of ragweed pollen allergen extract
Description: administered once a day over 10 days
Study NCT01224834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual tablet of ragweed pollen allergen extract
Description: administered once a day over 10 days
Study NCT00478192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: premix bag
Study NCT00478192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: premix bag
Study NCT02320513 — intervention group
Intervention type: OTHER
Intervention: Wearing activty monitoring device (Fitbit Flex)
Study NCT02320513 — intervention group
Intervention type: DEVICE
Intervention: Fitbit Flex
Study NCT00500344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lucentis (ranibizumab)
Description: intravitreal injection
Study NCT01790919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy for depression
Description: Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
Study NCT01790919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy for depression
Description: Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory.
Study NCT02680171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Goggles
Description: Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
Study NCT02680171 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-Shifting Goggles
Description: Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
Study NCT01481402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liothyronine
Description: Liothyronine 40 microgram per day
Study NCT01481402 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liothyronine
Description: 3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
Study NCT02215889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Study NCT01505231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.
Study NCT01505231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study NCT01462305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: goLITE
Description: goLITE at 30 minutes per day, within 30 minutes of waking in the morning
Study NCT01462305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
Study NCT04035525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MaxSimil® fish oil + CoQ10
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.
Study NCT04035525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice bran oil + CoQ10
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.
Study NCT04035525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10 as powder form
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.
Study NCT03989596 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks.
Study NCT03989596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
Study NCT04060797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular denervation
Description: Treating with endovascular denervation (EDN) at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
Study NCT04060797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA
Description: Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
Study NCT04060797 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PTA
Description: Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
Study NCT03560063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corin Optimised Positioning System
Description: Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
Study NCT03560063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard templating
Description: Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
Study NCT01067898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (cholecalciferol)
Description: vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
Study NCT01067898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil
Description: 10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
Study NCT01067898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
Study NCT01067898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: 1000 mg calcium per os every day for one year
Study NCT01067898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: 1000 mg calcium per os every day for one year
Study NCT05013242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
Study NCT05013242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visanne
Description: valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
Study NCT02862938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 ECT implant
Description: NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
Study NCT02862938 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham surgery
Study NCT04239352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentraxin 3 ; new biomarker
Description: Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component.